Acetaminophen And Codeine Phosphate


Lake Erie Medical Dba Quality Care Products Llc
Human Prescription Drug
NDC 49999-060
Acetaminophen And Codeine Phosphate is a human prescription drug labeled by 'Lake Erie Medical Dba Quality Care Products Llc'. National Drug Code (NDC) number for Acetaminophen And Codeine Phosphate is 49999-060. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Acetaminophen And Codeine Phosphate drug includes Acetaminophen - 300 mg/1 Codeine Phosphate - 30 mg/1 . The currest status of Acetaminophen And Codeine Phosphate drug is Active.

Drug Information:

Drug NDC: 49999-060
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Acetaminophen And Codeine Phosphate
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Acetaminophen And Codeine Phosphate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Lake Erie Medical Dba Quality Care Products Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ACETAMINOPHEN - 300 mg/1
CODEINE PHOSPHATE - 30 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 14 Sep, 2011
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 28 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA040419
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Lake Erie Medical DBA Quality Care Products LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:993781
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
UNII:362O9ITL9D
GSL05Y1MN6
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Full Opioid Agonists [MoA]
Opioid Agonist [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.
DEA Schedule:CIII
This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
49999-060-3030 TABLET in 1 BOTTLE (49999-060-30)14 Sep, 2011N/ANo
49999-060-6060 TABLET in 1 BOTTLE (49999-060-60)14 Sep, 2011N/ANo
49999-060-9090 TABLET in 1 BOTTLE (49999-060-90)14 Sep, 2011N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Acetaminophen and codeine phosphate acetaminophen and codeine phosphate acetaminophen acetaminophen codeine phosphate codeine anhydrous crospovidone magnesium stearate cellulose, microcrystalline povidone starch, corn stearic acid to off-white 3;m

Drug Interactions:

Drug interactions this drug may enhance the effects of other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other cns depressants, causing increased cns depression.

Boxed Warning:

Warning hepatotoxicity acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product.

Indications and Usage:

Indications and usage acetaminophen and codeine phosphate tablets are indicated for the relief of mild to moderately severe pain.

Warnings:

Warnings

General Precautions:

General acetaminophen and codeine phosphate tablets should be prescribed with caution in certain special risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, head injuries, elevated intracranial pressure, acute abdominal conditions, hypothyroidism, urethral stricture, addison's disease, or prostatic hypertrophy. ultra-rapid metabolizers of codeine - some individuals may be ultra-rapid metabolizers due to a specific cyp2d6*2x2 genotype. these individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. this rapid conversion results in higher than expected serum morphine levels. even at labeled dosage regiments, individuals who are ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion or shallow breathing. the prevalence of this cyp2d6 phenotype varies widely and has been estimated at 0.5 to 1% in chinese and japanese, 0.5 to 1% in his
panics, 1 to 10% in caucasians, 3% in african americans, and 16 to 28% in north africans, ethiopians and arabs. data is not available for other ethnic groups. when physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and should inform their patients about these risks and the signs of morphine overdose ( see precautions, nursing mothers ).

Dosage and Administration:

Dosage and administration dosage should be adjusted according to severity of pain and response of the patient. the usual adult dosage for tablets is: single doses (range) maximum 24 hour dose codeine phosphate 15 mg to 60 mg 360 mg acetaminophen 300 mg to 1000 mg 4000 mg the usual dose of codeine phosphate in children is 0.5 mg/kg. doses may be repeated up to every 4 hours. the prescriber must determine the number of tablets per dose, and the maximum number of tablets per 24 hours based upon the above dosage guidance. this information should be conveyed in the prescription. it should be kept in mind, however, that tolerance to codeine can develop with continued use and that the incidence of untoward effects is dose related. adult doses of codeine higher than 60 mg fail to give commensurate relief of pain but merely prolong analgesia and are associated with an appreciably increased incidence of undesirable side effects. equivalently high doses in children would have similar effects.

Contraindications:

Contraindications this product should not be administered to patients who have previously exhibited hypersensitivity to codeine or acetaminophen.

Adverse Reactions:

Adverse reactions the most frequently reported adverse reactions are drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea and vomiting. these effects seem to be more prominent in ambulatory than in non-ambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. other adverse reactions include allergic reactions, euphoria, dysphoria, constipation, abdominal pain, pruritus, rash, thrombocytopenia, agranulocytosis. at higher doses, codeine has most of the disadvantages of morphine including respiratory depression.

Drug Interactions:

Drug interactions this drug may enhance the effects of other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other cns depressants, causing increased cns depression.

Use in Pregnancy:

Pregnancy teratogenic effects. pregnancy category c codeine – a study in rats and rabbits reported no teratogenic effect of codeine administered during the period of organogenesis in doses ranging from 5 to 120 mg/kg. in the rat, doses at the 120 mg/kg level, in the toxic range for the adult animal, were associated with an increase in embryo resorption at the time of implantation. in another study a single 100 mg/kg dose of codeine administered to pregnant mice reportedly resulted in delayed ossification in the offspring. there are no adequate and well-controlled studies in pregnant women. acetaminophen and codeine phosphate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. nonteratogenic effects dependence has been reported in newborns whose mothers took opiates regularly during pregnancy. withdrawal signs include irritability, excessive crying, tremors, hyperreflexia, fever, vomiting, and diarrhea. these signs usually appear
during the first few days of life.

Overdosage:

Overdosage following an acute overdosage, toxicity may result from codeine or acetaminophen. signs and symptoms toxicity from codeine poisoning includes the opioid triad of pinpoint pupils, depression of respiration, and loss of consciousness. convulsions may occur. in acetaminophen overdosage, dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. renal tubular necrosis, hypoglycemic coma and coagulation defects may also occur. early symptoms following a potentially hepatotoxic overdose may include nausea, vomiting, diaphoresis and general malaise. clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion. treatment a single or multiple drug overdose with acetaminophen and codeine is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended. immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. assisted or controlled ventilation should also be considered. for respiratory depression due to overdosage or unusual sensitivity to codeine, parenteral naloxone is a specific and effective antagonist. gastric decontamination with activated charcoal should be administered just prior to n-acetylcysteine (nac) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. to obtain the best possible outcome, nac should be administered as soon as possible where impending or evolving liver injury is suspected. intravenous nac may be administered when circumstances preclude oral administration. vigorous supportive therapy is required in severe intoxication. procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication.

dependence:

Drug abuse and dependence controlled substance acetaminophen and codeine phosphate tablets are classified as a schedule iii controlled substance. abuse and dependence codeine can produce drug dependence of the morphine type and, therefore, has the potential for being abused. psychological dependence, physical dependence, and tolerance may develop upon repeated administration and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic medications.

Description:

Description acetaminophen and codeine phosphate is supplied in tablet form for oral administration. acetaminophen, 4'-hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. it has the following structural formula: codeine phosphate, 7,8-didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1) (salt) hemihydrate, a white crystalline powder, is a narcotic analgesic and antitussive. it has the following structural formula: each acetaminophen and codeine phosphate tablet usp (300 mg/30 mg) contains: acetaminophen usp . . . . . . . . . . . . . 300 mgcodeine phosphate usp . . . . . . . . . . . . . 30 mg each acetaminophen and codeine phosphate tablet usp (300 mg/60 mg) contains: acetaminophen usp . . . . . . . . . . . . . 300 mgcodeine phosphate usp . . . . . . . . . . . . . 60 mg in addition, each acetaminophen and codeine phosphate tablet usp contains the following inactive ingredients: crospovidone, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, stearic acid. acetaminophen chemical structure codeine phosphate chemical structure

Clinical Pharmacology:

Clinical pharmacology this product combines the analgesic effects of a centrally acting analgesic, codeine, with a peripherally acting analgesic, acetaminophen. pharmacokinetics the behavior of the individual components is described below. codeine – codeine is readily absorbed from the gastrointestinal tract. it is rapidly distributed from the intravascular spaces to the various body tissues, with preferential uptake by parenchymatous organs such as the liver, spleen and kidney. codeine crosses the blood-brain barrier, and is found in fetal tissue and breast milk. the plasma concentration does not correlate with brain concentration or relief of pain; however, codeine is not bound to plasma proteins and does not accumulate in body tissues. the plasma half-life is about 2.9 hours. the elimination of codeine is primarily via the kidneys, and about 90% of an oral dose is excreted by the kidneys within 24 hours of dosing. the urinary secretion products consist of free and glucuronide c
onjugated codeine (about 70%), free and conjugated norcodeine (about 10%), free and conjugated morphine (about 10%), normorphine (4%), and hydrocodone (1%). the remainder of the dose is excreted in the feces. at therapeutic doses, the analgesic effect reaches a peak within 2 hours and persists between 4 and 6 hours. see overdosage for toxicity information. acetaminophen – acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. the plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage. elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug. see overdosage for toxicity information.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility no adequate studies have been conducted in animals to determine whether acetaminophen and codeine have a potential for carcinogenesis or mutagenesis. no adequate studies have been conducted in animals to determine whether acetaminophen has a potential for impairment of fertility. acetaminophen and codeine have been found to have no mutagenic potential using the ames salmonella-microsomal activation test, the basc test on drosophila germ cells, and the micronucleus test on mouse bone marrow.

How Supplied:

How supplied each acetaminophen and codeine phosphate tablet usp 300 mg/15 mg tablet contains acetaminophen 300 mg and codeine phosphate 15 mg. it is available as a round, white to off-white tablet debossed with "2" on one side and an m on the other side. each acetaminophen and codeine phosphate tablet usp 300 mg/30 mg tablet contains acetaminophen 300 mg and codeine phosphate 30 mg. it is available as a round, white to off-white tablet debossed with "3" on one side and an m on the other side. 49999-060-06 49999-060-15 49999-060-12 49999-060-10 49999-060-20 49999-060-24 49999-060-30 49999-060-50 49999-060-60 49999-060-90 49999-060-00 49999-060-01 each acetaminophen and codeine phosphate tablet usp 300 mg/60 mg tablet contains acetaminophen 300 mg and codeine phosphate 60 mg. it is available as a round, white to off-white tablet debossed with "4" on one side and an m on the other side. store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. dispense in tigh
t, light-resistant container as defined in the usp. is a trademark of mallinckrodt inc. mallinckrodt inc. hazelwood, mo 63042 usa rev 06/2011 mallinckrodt covidien™ imprint code

Information for Patients:

Information for patients/caregivers do not take acetaminophen and codeine phosphate tablets usp if you are allergic to any of its ingredients. if you develop signs of allergy such as a rash or difficulty breathing stop taking acetaminophen and codeine phosphate tablets usp and contact your healthcare provider immediately. do not take more than 4000 milligrams of acetaminophen per day. call your doctor if you took more than the recommended dose. codeine may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. such tasks should be avoided while taking this product. alcohol and other cns depressants may produce an additive cns depression when taken with this combination product, and should be avoided. codeine is habit-forming. patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed. caution patients that some people have
a variation in a liver enzyme and change codeine into morphine more rapidly and completely than other people. these people are ultra-rapid metabolizers and are more likely to have higher-than-normal levels of morphine in their blood after taking codeine which can result in overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. in most cases, it is unknown if someone is an ultra-rapid codeine metabolizer. nursing mothers taking codeine can also have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. these higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. instruct nursing mothers to watch for signs of morphine toxicity in their infants including increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. instruct nursing mothers to talk to the baby's doctor immediately if they notice these signs and, if they cannot reach the doctor right away, to take the baby to an emergency room or call 911 (or local emergency services).

Package Label Principal Display Panel:

Image description


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.